Navigation Links
Ceres Announces Fiscal Year 2013 Financial Results

THOUSAND OAKS, Calif., Nov. 21, 2013 /PRNewswire/ -- Energy crop company Ceres, Inc. (Nasdaq: CERE) today announced financial results for the fiscal year ended August 31, 2013 and provided an update on its business in Brazil.

The company reported that plantings for the 2013-2014 sorghum growing season in Brazil have commenced and are expected to continue through December. With industrial processing of Ceres' sweet sorghum hybrids generally well established, these plantings consist primarily of smaller, multi-hybrid evaluations designed to determine yield potential, identify the best performing hybrids for specific regions and to demonstrate various crop management practices."Our goal this season is to clearly demonstrate the economic basis for sweet and high biomass sorghum cultivation and processing," said Richard Hamilton, President and Chief Executive Officer of Ceres. "We have made a number of adjustments to our product development process and go-to-market approach, with an emphasis on consistent execution of our crop management protocols."

Mr. Hamilton noted that field performance will largely determine the scale and pace at which the company's products will be adopted moving forward. "We have significantly increased yields of fermentable sugars since our first industrial evaluations in 2011 and we expect to continue to develop a stream of higher-performing hybrids that provide a greater buffer to variable growing conditions and crop management practices," he said.

Ceres Chief Financial Officer Paul Kuc indicated that the company is moving forward with previously reported plans to reduce expenses in fiscal year 2014. "The priority for our working capital will be product development and commercial activities related to sorghum and our near-term opportunity in Brazil. We will also continue to advance potentially high-value traits, like yield and drought resistance, in our pipeline for use in sorghum as well as in row crops," he said.


  • For the 2013-2014 season, Ceres expects to evaluate its sorghum hybrids at approximately 50 mills and mill suppliers. These evaluations include approximately 10 hybrids, including commercial and pre-commercial products. Plantings are expected to cover up to approximately 1,000 hectares compared to approximately 3,000 hectares the previous season due primarily to a greater focus among mills on field performance, which can be determined at a smaller scale than evaluations needed for confirming industrial performance. Approximately 30 mills evaluated the company's sorghum products last season.
  • The company has expanded the number of locations and scope of field evaluations of  pre-commercial products and advanced breeding materials in Brazil in order to better position its future products among various geographies, growing conditions and production practices. These breeding materials have demonstrated, among other characteristics, step increases in yields, greater yield stability, longer periods of industrial utilization and greater adaptation to various growing conditions and harvest times.
  • Former Brazil Agricultural Minister Roberto Rodrigues has agreed to chair a sorghum advisory council established by the company's Brazilian subsidiary. The council will provide strategic advice and support for the introduction of the biofuel crop in Brazil. Members represent companies in industrial ethanol processing, agricultural production and bioenergy.
  • In October, Ceres announced that the company extended a joint market development agreement with Syngenta in Brazil. Under the renewed agreement, Syngenta and Ceres will continue to collaborate on field evaluations with mills. Syngenta indicated that it plans to move forward with its evaluations aimed at registering additional crop protection products for sorghum.
  • In China, field evaluations of several Ceres' biotech traits in corn have demonstrated significantly higher grain yields under drought conditions. The company intends to seek out-licensing opportunities for certain of these traits in corn once further evaluations allow their commercial value to be more definitively determined.
  • In India, results from rice evaluations completed this month confirmed that genes developed by Ceres provided improved yield stability under drought and other stress conditions that routinely limit productivity. These genes are currently being introduced into breeding lines by the company's commercialization partner in India.
  • In October, Ceres reported that it would further align expenditures with its near-term commercial opportunity in Brazil, relocate its Northern Hemisphere sorghum breeding activities, reduce research and development expenditures for U.S. cellulosic feedstocks, reduce overall costs and conserve cash. These changes are expected to deliver cash savings of up to approximately $5.0 million in fiscal year 2014 and up to approximately $8.0 to $10.0 million annually thereafter.
  • YEAR-END FINANCIAL RESULTSTotal revenues for the year ended August 31, 2013 were $5.2 million compared to $5.4 million for the previous fiscal year due primarily to a decrease in collaborative research revenue.

    Cost of product sales was $6.2 million for the year ended August 31, 2013 compared to $2.4 million for the previous fiscal year. The increase was primarily due to write-down expenses of $2.2 million for obsolete seed inventory relating to the company's sweet sorghum products and $1.7 million for crop management services performed under certain sales incentive and performance-based promotional programs for the 2012-2013 growing season in Brazil.

    Research and development expenses decreased by $2.8 million to $16.4 million for the year ended August 31, 2013 compared to the previous fiscal year due primarily to reduced personnel and related expenses in the U.S. as well as reduced external R&D expenses.

    Selling, general and administrative expenses were $15.2 million for the year ended August 31, 2013 compared to $12.6 million for the previous fiscal year due primarily to increased personnel and related administrative expenses in Brazil.

    For the fiscal year ended August 31, 2013, Ceres reported a net loss of $32.5 million, or $1.31 per share, compared to a net loss of $29.4 million, or $2.18 per share, for the fiscal year ended August 31, 2012.

    At August 31, 2013, cash and cash equivalents and marketable securities totaled $30.5 million.

    CONFERENCE CALL AND WEBCAST INFORMATIONCeres has scheduled a conference call for 4:30 p.m. EST (1:30 p.m. PST) today to discuss year-end results. The webcast of the conference call may be accessed at Audio of the teleconference is also available by dialing:

    North America callers:
    (877) 838-4153

    International callers:
    +1 (720) 545-0037

    An audio replay of the call will be available two hours after the conclusion of the live call, and remain available on the Ceres website for 30 days.

    ABOUT CERESCeres, Inc. is an agricultural biotechnology company that markets seeds for energy crops used in the production of renewable transportation fuels, electricity and bio-based products. The company combines advanced plant breeding and biotechnology to develop products that can address the limitations of first-generation bioenergy feedstocks, increase biomass productivity, reduce crop inputs and improve cultivation on marginal land. Its development activities include sweet sorghum, high-biomass sorghum, switchgrass and miscanthus. Ceres markets its products under its Blade brand.

    This press release may contain forward-looking statements. All statements, other than statements of historical facts, including statements regarding Ceres' efforts to develop and commercialize its products, short-term and long-term business strategies, market and industry expectations, future operating metrics, product yields and future results of operations and financial position, are forward-looking statements. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond Ceres' control. Factors that could materially affect actual results can be found in Ceres' filings with the U.S. Securities and Exchange Commission. Ceres undertakes no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing Ceres' views as of any date subsequent to the date of this press release.CERES, INC. AND SUBSIDIARYCondensed Consolidated Statements of Operations (In thousands, except share and per share amounts)(Unaudited) Three Months Ended
    August 31,  Year Ended
    August 31, 2013201220132012Revenues:Product sales 

    432Collaborative research and government grants 

    8981,1614,7814,939Total revenues 

    8981,1645,2435,371Cost and operating expenses:Cost of product sales 

    1,1325076,2452,384Research and development 

    3,6173,63416,40119,155Selling, general and administrative 

    3,4883,67315,18712,634Total cost and operating expenses 

    8,2377,81437,83334,173Loss from operations 

    (7,339)(6,650)(32,590)(28,802)Interest expense 

    (11)(1)(46)(560)Interest income 

    193012639Other expense

    ———(84)Loss before income taxes 

    (7,331)(6,621)(32,510)(29,407)Income tax expense

    —(2)(1)(3)Net loss 

    (6,623)$   (32,511)$
    (29,410)Basic and diluted net loss per share

    (2.18)Basic and diluted weighted average outstanding common shares used for net loss per share

    24,886,14025,509,94024,796,03013,488,336CERES, INC. AND SUBSIDIARYCondensed Consolidated Balance Sheets (In thousands, except share amounts)August 31,August 31,20132012AssetsCurrent assets:Cash and cash equivalents 

    21,069Marketable securities

    21,63033,565Prepaid expenses 

    7911,050Accounts receivable


    20841Other current assets 

    157278Total current assets 

    32,43657,568Property and equipment, net 

    4,6335,756Marketable securities

    —5,720Other assets 

    109203Total long-term assets

    4,74211,679Total assets 

    9,247Liabilities and Stockholders' EquityCurrent liabilities:Accounts payable and accrued expenses 

    5,476Deferred revenue

    —701Deferred rent

    1831Current portion of long-term debt 

    154134Total current liabilities 

    3,9976,342Deferred rent

    9388Long-term debt, net of current portion 

    82256Total liabilities 

    4,1726,686Commitments and contingenciesStockholders' equity:Common stock, $0.01 par value; 490,000,000 shares authorized; 24,897,199 shares issued and outstanding at August 31, 2013; 24,549,029 shares issued and outstanding at August 31, 2012.

    248245Additional paid-in capital

    308,038304,672Accumulated other comprehensive loss 

    (696)(283)Accumulated deficit 

    (274,584)(242,073)Total stockholders' equity 

    33,00662,561Total liabilities and stockholders' equity 


    SOURCE Ceres, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Related biology technology :

    1. Ceres Expands Board of Directors with former BP Chief Scientist and Undersecretary of Energy Steven Koonin
    2. Ceres Receives $3.5 million from USAID for Trait Stacks
    3. Ceres and Syngenta to Collaborate on Sweet Sorghum Market Development
    4. Ceres Announces Webcast of Fiscal Year 2013 Financial Results
    5. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
    6. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
    7. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
    8. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
    9. GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results
    10. WuXi PharmaTech Announces Third-Quarter 2011 Results
    11. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
    Post Your Comments:
    (Date:11/25/2015)... 25, 2015  PharmAthene, Inc. (NYSE MKT: PIP) announced ... stockholder rights plan (Rights Plan) in an effort to ... (NOLs) under Section 382 of the Internal Revenue Code ... PharmAthene,s use of its NOLs could be substantially limited ... in Section 382 of the Code. In general, an ...
    (Date:11/25/2015)... 25, 2015  Neurocrine Biosciences, Inc. (Nasdaq: NBIX ... and CEO of Neurocrine Biosciences, will be presenting at ... New York . .   ... approximately 5 minutes prior to the presentation to download ... presentation will be available on the website approximately one ...
    (Date:11/25/2015)... , November 25, 2015 ... Report is a professional and in-depth study on ...      (Logo: ) , ... the industry including definitions, classifications, applications and industry ... for the international markets including development trends, competitive ...
    (Date:11/24/2015)... , Nov. 24, 2015 Cepheid (NASDAQ: ... speaking at the following conference, and invited investors to ... NY      Tuesday, December 1, 2015 at 11.00 ... NY      Tuesday, December 1, 2015 at 11.00 ... Conference, New York, NY      Tuesday, ...
    Breaking Biology Technology:
    (Date:11/17/2015)...  Vigilant Solutions announces today that Mr. Dick ... --> --> Mr. ... partnership at TPG Capital, one of the largest global ... in revenue.  He founded and led TPG,s Operating Group, ... from 1997 to 2013.  In his first role, he ...
    (Date:11/12/2015)... 12, 2015  A golden retriever that stayed healthy ... (DMD) has provided a new lead for treating this ... Broad Institute of MIT and Harvard and the University ... Cell, pinpoints a protective gene ... disease,s effects. The Boston Children,s lab of Lou ...
    (Date:11/11/2015)... 2015   MedNet Solutions , an innovative SaaS-based eClinical ... is pleased to announce that it will be a Sponsor ... event, to be held November 17-19 in Hamburg ... demonstrations of iMedNet , MedNet,s easy-to-use, proven ... has been able to deliver time and cost savings ...
    Breaking Biology News(10 mins):